Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Sponsor: Oruka Therapeutics, Inc.
Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
Official title: A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-03
Completion Date
2029-04
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
ORKA-002
ORKA-002 administered by subcutaneous (SC) injection
Placebo
Placebo administered by subcutaneous (SC) injection